Awards Grants and Projects

Optimata’s CSO Zvia Agur Named Finalist for EU Prize for Women Innovators 2016

Nine outstanding women entrepreneurs who have brought their breakthrough ideas to the market are entering the final stage of the EU Prize for Women Innovators 2016. The shortlist, which includes Optimata’s Founder and CSO, Professor Zvia Agur, was announced today by the European Commission. The contestants have all founded or co-founded successful companies based on their innovative ideas.

READ MORE
TRAIN-ERS

OPTIMTA focuses on mathematical/statistical modelling-based personalized medicine to enable patients receive the best drug therapy. Given that the stress response has been implicated in multiple diseases, including in melanoma patients that are subject to immunotherapy, it is important to determine if endoplasmic reticulum (ER) stress markers can be used as predictive markers of disease development and treatment response.

READ MORE
MEL-PLEX

Optimata recently became a partner in the new MELanoma disease comPLEXity (MEL-PLEX) research program, aimed at applying translational cancer systems biology and cancer systems medicine to study novel treatment options for personalized, patient-tailored melanoma therapies.

READ MORE
DDMoRe

Optimata is a participant in the Drug Disease Model Resources (DDMoRe) consortium, which was founded in 2011 by pharma partners, academics and SMEs across Europe. DDMoRe develops a public drug and disease model repository supported by an open source interoperability framework which will provide access to existing and future modeling tools.

READ MORE
APO-DECIDE

Optimata is a member of the Apoptosis Modeling for Treatment Decisions in Colorectal Cancer (APO-DECIDE) consortium, which tackles the problem of chemotherapy resistance in colorectal cancer.

READ MORE
Office of the Chief Scientist

Optimata was awarded a grant from the Office of the Chief Scientist of the Israeli Ministry of Commerce and Industry (OCS) for the development of Optimata Virtual Patient (OVP).

READ MORE